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1290The recent development of po-
tent antiplatelet therapy has led
to a decrease in the rate of
recurrent ischemic events and
mortality despite a constant in-
crease in major bleeding compli-
cations and a more liberal use
of allogeneic red blood cell (RBC)
transfusion (1–3). Bleeding and/
or transfusion have been re-
peatedly associated with an in-
creased risk for adverse outcomes,
including ischemic complica-
tions, myocardial infarction, and
death (4–6).
See page 1297
Making the right decisions for
patients with acute coronary syn-
dromes (ACS) presenting with
anemia and/or major bleeding
events remains a clinical chal-
lenge. Indeed, the interruptionof effective antithrombotic treatment can lead to fatal
thrombosis. RBC transfusion represents another challenging
issue, with studies suggesting that the conservative use of
RBC transfusion is more favorable in hemodynamically stable
patients (7–9).
Transfusion by itself has been shown to be an indepen-
dent risk factor for recurrent ischemic events and mortality
(10–12), although the causal link between bleeding or
transfusion and mortality has not been fully elucidated yet.
We previously demonstrated that in vitro RBC transfusion
increases platelet activation and aggregation in healthy vol-
unteers and can potentially contribute to excess risk and a
higher rate of recurrent thrombotic event observed in
transfused patients with ACS (13).
To further explore the consequences of RBC transfusion on
platelet reactivity and inﬂammatory response, we conducted
the Impact of Transfusion of Red Blood Cell on Platelet
Activation and Aggregation Studied With Flow Cytometry
Use and Light Transmission Aggregometry (TRANS-
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Methods
Study population. The TRANSFUSION-2 study is a
cross-sectional observational, prospective study conducted
by the Allies in Cardiovascular Trials Initiatives and Orga-
nized Networks Group at Institut de Cardiologie, Pitié-
Salpêtrière University Hospital (Paris, France). Patients with
documented coronary artery disease or without coronary
artery disease in whom an allogeneic RBC transfusion was
prescribed were enrolled in the study. Inclusion criteria
were: 1) age >18 years; 2) stable hemodynamic status; and
3) review of and agreement with the study protocol. Anti-
platelet therapy with aspirin, clopidogrel, prasugrel, or tica-
grelor was allowed. Exclusion criteria were: 1) previous RBC
transfusion in the past 7 days; 2) hemodynamic instability
with or without a cardiac assist device; 3) glycoprotein IIb/
IIIa inhibitor administration within the past 7 days; 4) septic
status at the time of transfusion; 5) use of steroidal and
nonsteroidal anti-inﬂammatory drugs; 6) a low platelet
count (<100  106/l); and 7) concomitant transfusion of
platelets. Written informed consent was obtained before
participation, and this study was approved by the Pitié-
Salpêtrière University Hospital Ethics Committee (Comité
de Protection des Personnes Participants à la Recherche
Biomédicale). The study was conducted and funded by the
Allies in Cardiovascular Trials Initiatives and Organized
Networks study group (http://www.action-coeur.org) and
performed within the Institut National de la Santé et de la
Recherche Médicale unit UMRS 937. A research grant was
also obtained from Société Française de Cardiologie and
Fédération Française de Cardiologie.
Data collection. All clinical and biological data from pa-
tients who provided informed consent were collected into a
prospective, Web-based registry, as well as drug intake to
evaluate drug-drug interactions. ABO type, rhesus group,
number of units of recipient blood, and dates of collection
and thawing were also obtained for each transfusion pack.
Preparation of RBC packs was done according to French
legislation (http://www.dondusang.net), and RBCs were
obtained at our institution using the classic principle of
centrifugation of total blood using saline-adenine-
glucose-mannitol as the additive solution, followed and
conserved between 2C and 6C for a maximum of 42 days.Squibb, Boehringer-Ingelheim, Duke Institute, Eli Lilly, Europa, GlaxoSmithKline,
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1291Blood sampling and measurements. Blood was collected
into Becton Dickinson (Franklin Lakes, New Jersey) 3.2%
citrate Vacuette tubes after having discarded the ﬁrst 2 ml to
4 ml of blood to avoid spontaneous platelet activation from a
peripheral vein in the same fashion before and after trans-
fusion. Blood samples were processed for platelet function
testing within 2 h after drawing. Platelet reactivity was tested
at baseline on blood drawn just before RBC transfusion, and
a second blood draw was performed 12 to 36 h after the end
of RBC transfusion. Plasma samples were obtained for each
patient before and after transfusion by centrifugation of
blood samples at 3,000 g for 20 min, and aliquots of 0.6 ml of
plasma were stored at 80C until assay.
Light transmission aggregometry. Platelet-rich plasma
was obtained by centrifugation of citrated whole blood at
100g for 10 min at room temperature. Platelet-poor plasma
was obtained by further centrifugation at 4,500g for 15 min.
In vitro platelet aggregation in platelet-rich plasma was
measured at 37C using light transmission aggregometry
(LTA) (model 490-4D; Chrono-Log Corporation, Kordia,
the Netherlands) and was induced by 4 different agonists:
1) adenosine diphosphate (ADP) 20 mmol/l (Sigma-
Aldrich, Saint Quentin Fallavier, France); 2) arachidonic
acid (AA) 1.25 mmol/l (Sigma-Aldrich); 3) collagen
2 mg/ml (Helena Biosciences, Tyde and Wear, United
Kingdom); and 4) thrombin receptor–activated peptide
20 mmol/l. Maximal platelet aggregation (MPA) and re-
sidual platelet aggregation (RPA) measured 6 min after the
induction of aggregation were recorded for all agonists.
Pre-speciﬁed criteria used to deﬁne nonevaluable samples
were lack of sufﬁcient signal, hemolysis, and platelet-rich
plasma platelet count <150,000/ml and an unstable base-
line signal.
Flow cytometry. Flow cytometry was performed <2 h after
venipuncture for P-selectin measurement. The phosphory-
lation of vasodilator-stimulated phosphoprotein was
measured within 24 to 48 h using a Beckman Coulter
FC500 cytometer (Beckman Coulter, Villepinte, France).
To determine platelet P-selectin expression, blood sam-
ples previously activated by a dose of 10 or 20 mmol/l of
ADP were mixed with saturated concentrations of anti-
CD62p-PE (Beckman Coulter) monoclonal antibody and
anti-CD41a–ﬂuorescein isothiocyanate monoclonal anti-
body (Beckman Coulter). After staining with antibodies,
samples were incubated for 30 min in the dark and diluted
with 1 ml of Isoﬂow Sheath ﬂuid (Beckman Coulter).
Samples were immediately processed for ﬂow cytometric
analysis. To determine platelet CD62P expression, indi-
vidual platelets were identiﬁed by size (forward and scatter)
and anti-CD41a–ﬂuorescein isothiocyanate immunoﬂuo-
rescence using a logarithmic scaled dot plot. P-selectin
expression on the surface of platelets was deﬁned as posi-
tive for anti-CD62P-PE. Variation in activation corre-
sponded to the percent of gated platelets after activation
by agonist minus the percent of gated platelets at rest.
The level of P-selectin expression at rest was subtractedfrom the raw value of P-selectin expression after activation
by ADP to compare the variation in delta of P-selection
expression.
Vasodilator-stimulated phosphoprotein platelet reactivity
index. Vasodilator-stimulated phosphoprotein (VASP)
phosphorylation was measured using platelet VASP kits
(Diagnostica Stago, Asnières, France) according to the
manufacturer’s instructions. Brieﬂy, blood samples were
incubated in vitro with ADP and/or prostaglandin E1
(PGE1) before ﬁxation. The platelet population was iden-
tiﬁed on its forward-scatter and side-scatter distributions,
and 5,000 platelet events were gated and analyzed for
mean ﬂuorescence intensity (MFI). The MFI corresponding
to each experimental condition (PGE1 and ADP þ PGE1)
was determined to establish a ratio directly correlated
with the VASP phosphorylation state. The VASP platelet
reactivity index (PRI) was calculated from the MFI of
each condition according to the formula: VASP PRI ¼
[(MFIPGE1  MFIPGE1þADP)/MFIPGE1]  100. All mea-
surements were performed in our research laboratory on
thrombosis (the Institut National de la Santé et de la
Recherche Médicale unit UMRS 937) according to previ-
ously published methods (14–17). The technicians were
blinded to patients’ identities and characteristics.
Biomarkers. Soluble CD40 ligand levels were measured
using a human soluble CD40 ligand enzyme-linked
immunosorbent bioassay (Biovendor, Karasek, Czech Re-
public). Tumor necrosis factor–alpha and interleukin-
6 levels were measured using Quantikine sandwich enzyme
immunoassays (AssayPro, St. Charles, Missouri) according
to the manufacturer’s instructions. C-reactive protein lev-
els were quantiﬁed using commercially available enzyme-
linked immunosorbent assay kits (Zymutest; HypenBioMed,
Neuville-sur-Oise, France). Plasminogen activator inhibitor-1,
D-dimer, and von Willebrand factor antigen concentrations
were measured using Asserachrom kits (Diagnostica Stago).
Tissue factor pathway inhibitor was measured using sandwich
enzyme immunoassays (USCNK, Wuhan, China). All mea-
surements were assessed in duplicate.
Study endpoints. The main endpoint was the relative
change in MPA in response to ADP, expressed as the per-
cent of change between baseline and post-transfusion mea-
surement ([MPApost-transfusion  MPAbaseline]/MPAbaseline).
Other endpoints were the relative changes of platelet aggre-
gation with other agonists or other platelet function tests and
changes in biomarkers before and after transfusion ([post-
transfusion value  baseline value]/baseline value).
Clinical follow-up. Patients were followed for 30 days
through outpatient consults. Physicians noted the occur-
rence of major cardiovascular and cerebrovascular events,
including death, stroke, recurrent myocardial infarction,
urgent revascularization, and deﬁnite and probable stent
thrombosis (per the Academic Research Consortium de-
ﬁnition), as well as major and minor bleeding events ac-
cording to the Bleeding Academic Research Consortium
(BARC) deﬁnition (18).
Table 1 Demographics (n ¼ 61)
Demographics and risk factors
Age (yrs) 68.5  16.1
Men 38 (62.3)
Active smokers 21 (34.4)
Diabetes 12 (19.7)
Hypertension 16 (26.2)
Dyslipidemia 30 (49.2)
BMI (kg/m2) 24.6  4.6
Renal insufﬁciency (creatinine clearance <60 ml/min) 25 (40.9)
Medical history
CAD 35 (57.4)
Angioplasty 27 (44.3)
Clinical presentation
STEMI or NSTEMI 24 (39.3)
Unstable angina 9 (14.8)
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1292Statistical analyses. On the basis of our previous study
(19), at least 60 transfused patients were needed to yield
80% power with a risk for alpha error of 0.05 to demonstrate
a difference of 10% relative change in MPA before and
after transfusion.
Means and standard deviations are used to report the
results. Data were analyzed using paired Student t tests. A
conﬁrmatory analysis using the Wilcoxon rank test was
also performed to assess statistical signiﬁcance in case of a
possible non-Gaussian distribution. Correlations between
RBC storage duration and platelet aggregation data were
tested using the Pearson test. Statistical tests were per-
formed using GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego, California). All tests
were 2 sided, with a statistical threshold for signiﬁcance
of 0.05.Cardiac insufﬁciency 11 (18.0)
Others 17 (27.9)
Reason for RBC transfusion
Bleeding and anemia 6 (8.2)
Anemia without external bleeding 55 (91.8)
Length of stay in hospital (days) 12 (6–20)
Biology on admission
Troponin I (mg/ml) 5.8  4.35
Negative troponin 37 (60.6)
Baseline hemoglobin (g/dl) 7.8  1.1
CRP (mg/l) 36 (13.5–75.9)
Fibrinogen (g/l) 5.1  1.8
Platelet count (103/mm3) 265  146
Proteins (g/l) 60.1  12.9
Creatinine clearance (ml/min) 56  6.15
Creatinine (mmol/l) 155  123
Antithrombotic treatment
ASA 45 (73.7)
Maintenance dose (mg/day) 81.9  15.6
Clopidogrel 75 mg 28 (45.9)
Prasugrel 10 mg 5 (8.2)
Loading dose within 24 h 9 (14.7)
GP IIb/IIIa inhibitors 0 (0)
Anticoagulant agents 37 (60.6)
RBC transfusion
Number of RBC packs 2 (1–6)
RBC storage duration (days) 18.8  12.2
Group O 34 (55.7)
Group A 18 (29.5)
Group B 7 (11.4)
Group AB 2 (3.3)
Post-transfusion hemoglobin (g/dl) 10.1  0.12
Pre-transfusion WBC count (109/l) 10.04  3.78
Post-transfusion WBC count (109/l) 9.65  3.50
Values are mean  SD, n (%), or median (range). Data on clinical presentation represent culprit
events within the same hospitalization.
ASA ¼ acetylsalicylic acid; BMI ¼ body mass index; CAD ¼ coronary artery disease; CRP ¼
C-reactive protein; GP ¼ glycoprotein; NSTEMI ¼ non–ST-segment elevation myocardial infarction;
RBC¼ red blood cell; STEMI ¼ ST-segment elevation myocardial infarction; WBC ¼ white blood cell.Results
Study population and RBC transfusion. Sixty-one pa-
tients were included in the TRANSFUSION-2 study.
Baseline characteristics are presented in Table 1. Thirty-
three patients had suspected ACS treated with both
P2Y12 inhibitors and aspirin, and the remaining 28 patients
were hospitalized for other cardiac diseases treated with
aspirin only or without any antiplatelet agent. Our study
population was a high-risk population: one-ﬁfth had dia-
betes, and 40.9% had renal insufﬁciency. Two-thirds of
the patients were treated with aspirin and proton pump
inhibitors. The 33 patients with ACS treated with dual-
antiplatelet therapy received clopidogrel 75 mg (n ¼ 28),
and 5 patients received prasugrel 10 mg. The mean
baseline hemoglobin level before transfusion was 7.8  1.1
g/dl, and the distribution of ABO blood types was 55.7%
(n ¼ 34) in group O, 29.5% (n ¼ 18) in group A, 11.4%
(n ¼ 7) in group B, and 3.3% (n ¼ 2) in group AB. The
vast majority of the patients received 2 packs of RBCs
(80%), leading to a mean and signiﬁcant rise of 2.3 g/l
in hemoglobin. The repartition of ABO blood type of
the transfused packs matched perfectly the patients’ blood
types, according to the transfusion rules. Patients included
in this study did not receive any other blood products
(plasma or platelet concentrates) during the study period,
and there was no substantial modiﬁcation of the trans-
fused patients’ medications between the 2 sampling pe-
riods (<24 h).
Effect of RBC transfusion on platelet aggregation
measured by LTA. Results of platelet aggregation
measured by LTA before and after transfusion in response to
ADP are presented in Figure 1. Compared with baseline
values, transfusion resulted in an 11.6% relative increase in
MPA and a 10.8% increase in RPA after platelet activation
by ADP (p ¼ 0.004 and p ¼ 0.005, respectively). The re-
sults of LTA in response to other agonists are shown in
Table 2. Platelet reactivity was also increased by 11.8% for
MPA and 12.7% for RPA with thrombin receptor–activatedpeptide activation (p ¼ 0.04 and p ¼ 0.02, respectively), but
no signiﬁcant difference was found after activation by a
nonspeciﬁc agonist (collagen) or by AA, exploring the Cox-1
inhibition pathway.
Figure 1
Platelet Reactivity Before and After RBC Transfusion Measured by MPA in Response to ADP 20 mmol/l and by RPA in the Entire
Study Population
ADP ¼ adenosine diphosphate; MPA ¼ maximal platelet aggregation; RBC ¼ red blood cell; RPA ¼ residual platelet aggregation. *p < 0.05 for comparison with baseline.
Table 2
Platelet Reactivity Before and After RBC Transfusion
in the Study Population (n ¼ 61) Measured With LTA,
Expressed by MPA and RPA
Variable
Baseline After Transfusion
p ValueMean SD Mean SD
ADP 20 mmol/l
MPA (%) 52.7 20.5 58.8 19.5 0.004*
RPA (%) 47.9 23.9 53.1 22.2 0.005*
AA 1.25 mmol/l
MPA (%) 13.4 24.2 17.0 25.0 0.46
RPA (%) 12.9 24.1 15.6 24.3 0.63
Collagen 2 mg/ml
MPA (%) 21.5 21.4 21.02 20.4 0.55
RPA (%) 20.6 21.5 20.4 20.0 0.86
TRAP
MPA (%) 49.3 23.4 55.1 24.5 0.04*
RPA (%) 44.7 25.4.9 50.4 27.2 0.02*
*p < 0.05 for comparison with baseline.
AA ¼ arachidonic acid; ADP ¼ adenosine diphosphate; LTA ¼ light transmission aggregometry;
MPA ¼ maximal platelet aggregation; RBC ¼ red blood cell; RPA ¼ residual platelet aggregation;
SD ¼ standard deviation; TRAP ¼ thrombin receptor–activated peptide.
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1293Effect of RBC transfusion on platelet activation
measured by ﬂow cytometry. Results for VASP PRI and
changes in P-selectin expression are reported in Figure 2.
The effect of transfusion on platelet aggregation was con-
ﬁrmed by a relative increase of 20.7% (p ¼ 0.002) in
the VASP PRI, a speciﬁc marker of the P2Y12 receptor
and ADP pathway. Conversely, there was a relative increase
of 8.3% in P-selectin expression, a marker of platelet activa-
tion, after transfusion of RBCs when 10 mmol/l ADP was
used as an agonist (p ¼ 0.07). This difference was blunted
by the use of 20 mmol/l ADP (2% increase; p ¼ 0.11).
Effect of RBC storage duration and blood type on
platelet activation. The median length of conservation
of the RBC packs before administration was 18.8 days
(interquartile range: 11 to 26 days; maximum 36 days,
minimum 3 days). We found no correlation between RBC
storage duration and the change in platelet aggregation
or platelet activation with LTA (r ¼ 0.07 for ADP, r ¼
0.03 for collagen, r ¼ 0.17 for AA, r ¼ 0.03 for thrombin
receptor–activated peptide). Similar results were obtained
for P-selectin expression (r ¼ 0.03 for both ADP condi-
tions). However, we found a signiﬁcant correlation be-
tween the increase in VASP PRI after transfusion and the
duration of conservation (r ¼ 0.34, p ¼ 0.009).
There was no clear impact of ABO blood type on platelet
reactivity (MPA with ADP 20 mmol/l measured by LTA),
as no major difference was found for blood type (þ5.89% for
group O [n ¼ 34], þ6.05% for group A [n ¼ 18], 1.25%
for group B [n ¼ 7], and þ9.7% for group AB [n ¼ 2];
p ¼ 0.77 for trend).Effect of RBC transfusion on inﬂammatory and throm-
botic biomarkers. Results of measurements of inﬂamma-
tory and thrombotic biomarkers and changes before and
after transfusion are reported in Table 3. We did not ﬁnd
any signiﬁcant changes between the pre-transfusion and
post-transfusion measurements.
Subgroup analysis. In an exploratory subgroup analysis, we
evaluated the results in patients treated with P2Y12 inhibitors
compared with those not receiving P2Y12 inhibitors. As
Figure 2
Variation in Platelet Aggregation and Activation Measured by Flow Cytometry With the VASP PRI and With P-Selectin
Expression With 10 mmol/l ADP and 20 mmol/l ADP Measured at Baseline and After Transfusion in the Entire Study Population
ADP ¼ adenosine diphosphate; PRI ¼ platelet reactivity index; VASP ¼ vasodilator-stimulated phosphoprotein. *p < 0.05 for comparison with baseline.
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1294expected, coronary patients treated with P2Y12 inhibitors
had lower baseline values of platelet reactivity whatever
the test used (data not shown). Platelet reactivity after
RBC transfusion was predominantly increased in coronary pa-
tients treated with P2Y12 inhibitors when measured by LTA
(relative increases of 20.4%, p¼ 0.002, and 15.6%, p¼ 0.03, for
MPA and RPA, respectively) compared with noncoronary pa-
tients not receiving P2Y12 inhibitors (relative increases of 4.7%,
p¼ 0.20, and 0.7%, p¼ 0.40, forMPAandRPA, respectively).
Short-term outcomes. Clinical follow-up was obtained in
all patients at 1-month follow-up. The mean length of stay
in the hospital was 12 days for transfused patients. Three
patients, all from the coronary group, died during theTable 3
Results of Biomarkers Measured at Base
Entire Study Population
Biomarker
Baseline
Mean SD
Inﬂammation
TNF-a (pg/ml) 34.6 29.4
CRP (mg/ml) 39.6 44.3
IL-6 (pg/ml) 13.8 22.5
PAI-1 (ng/ml) 13.8 22.5
Thrombosis
D-dimer (ng/ml) 2,942 2,989
TFPI (ng/ml) 91.3 44.0
sCD40L (ng/ml) 1.59 2.1
vWF:Ag (%) 155.4 98.4
*p < 0.05 for comparison with baseline.
CRP¼ C-reactive protein; IL-6 ¼ interleukin-6; PAI-1 ¼ plasminogen activat
TFPI ¼ tissue factor pathway inhibitor; TNF-a ¼ tumor necrosis factor–alphahospitalization period, 1 from a fatal myocardial infarction,
1 from gastrointestinal bleeding, and 1 from septic shock.
The rate of major cardiovascular and cerebrovascular events
was 11.5% (n ¼ 7). The rate of additional bleeding (per the
BARC deﬁnition), not counting the initial RBC trans-
fusion, was 9.8% (n ¼ 6), including 2 BARC 3 events and
4 BARC 1 or 2 events.Discussion
The evidence on the impact of RBC transfusion in patients
is limited, and although several hypotheses have been
described regarding the pathophysiological changes inducedline and After Transfusion in the
After Transfusion
p ValueMean SD
39.4 36.2 0.31
41.7 48.1 0.15
12.8 19.7 0.72
12.8 19.7 0.61
2,947 2,922 0.31
98.4 36.1 0.35
1.65 2.5 0.90
165.5 116 0.44
or inhibitor–1; sCD40L ¼ soluble CD40 ligand; SD ¼ standard deviation;
; vWF:Ag ¼ von Willebrand factor antigen.
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1295after RBC administration (20), we still do not fully under-
stand the mechanisms that could explain such deleterious
effects. In the TRANSFUSION-2 study, we explored the
consequences of RBC transfusion on platelet reactivity and
inﬂammatory response in anemic patients with or without
coronary artery disease and treated accordingly with or
without antiplatelet agents.
The results of this study can be summarized as follows.
First, we demonstrated that platelet reactivity measured
using 3 different platelet function tests increases in anemic
coronary and noncoronary patients after RBC transfusion.
Second, platelet reactivity increases with platelet function
tests exploring the P2Y12 receptor pathway (activated by
ADP) but not with tests exploring the AA pathway or with
nonspeciﬁc agonists such as collagen. Third, we found no
signiﬁcant variations in levels of inﬂammatory or thrombotic
biomarkers after RBC transfusion, suggesting a limited
systemic effect of this therapy. Finally, we found no rela-
tionship between storage duration or blood type and the
increase in platelet aggregation after RBC transfusion, with
the exception of the increase in the VASP PRI, which seems
to be correlated with the duration of conservation of RBC
packs.
The present ﬁndings obtained in clinical situations are
novel and conﬁrm our previous work performed in vitro with
blood from healthy volunteers. In the TRANSFUSION-1
study (19), we previously demonstrated a 13.9% relative
increase in MPA after RBC transfusion from healthy vol-
unteers, a magnitude of change similar to that reported in
the present TRANSFUSION-2 study (11.8%). This ﬁnding
is supported by our ﬂow cytometric measurements showing a
simultaneous increase of VASP phosphorylation, reﬂecting
the degree of P2Y12 receptor inhibition and a similar trend
for P-selectin expression (not signiﬁcant), a global marker
of platelet activation (21). More important, we were able to
show that this increase of platelet reactivity was predomi-
nantly found with platelet function tests using agonists of
the ADP-P2Y12 receptor pathway, as demonstrated by the
results of LTA using ADP as an agonist and the major in-
crease in VASP PRI, suggesting again an implication of this
pathway in the platelet activation effect of RBC transfusion.
According to our ﬁndings, one hypothesis that can be
offered is that RBC transfusion might directly affect platelet
reactivity through activation of the P2Y12 platelet receptor or
within the ADP pathway by agonists or mediators contained
in RBC packs. The liberal quantities of ADP contained in
RBCs have been shown to play a role in platelet adhesion
(22) and might represent a potential stimulus for platelet
activation and aggregation, a hypothesis already supported
by our previous in vitro experiments. The strong correlation
found in the present study between increased VASP PRI
and the duration of RBC storage reinforce the hypothesis of
an activation of this pathway through ADP and a possible
effect on outcomes, as suggested in a previous study in
critically ill patients (23), although this ﬁnding deserves to be
explored in further studies.Another possible explanation of our results is that the
increase in platelet reactivity found in the P2Y12 pathway is
attributable mainly to the group of coronary patients as a
consequence of their physicians’ decisions to stop P2Y12
inhibitors. In recent studies (24,25), platelet recovery was
estimated to be as high as 10% within the ﬁrst 24 h of
clopidogrel discontinuation, a magnitude that is consistent
with our present ﬁnding. However, this hypothesis is un-
likely to explain our ﬁnding, as only half of the population
was treated with P2Y12 inhibitors, and the VASP results
show increased platelet reactivity in both coronary patients
treated with P2Y12 inhibitors and noncoronary patients not
treated with thienopyridine. Even if these arguments are not
supportive of the interruption hypothesis as the unique
mechanism for the increase in platelet reactivity found in our
study, this hypothesis cannot be excluded.
Study limitations. The lack of a control group should be
acknowledged as a theoretical limitation of our study.
Several controls, such as anemic or nonanemic patients or
healthy volunteers receiving RBC transfusion or another
vascular solution, and treated with different regimens of
antiplatelet agents, would have been necessary, but such
situations are difﬁcult to conceive in clinical research and our
previous in vitro model of RBC transfusion in nonanemic
healthy volunteers support our ﬁndings. Another limitation
is whether this effect of RBC transfusion could have been
differentiated from that of treatment interruption, for which
another study design would have been needed. However, we
believe that our study raises platelet recovery as an issue in
the context of RBC transfusion in stable patients and that its
effect only adds to the increase in platelet reactivity after
RBC transfusion. The subgroup analysis of the ACS group
was meant only to be exploratory and must be interpreted
with caution, as this study was not powered to conduct for
such an analysis. Finally, the magnitude of the increase in
platelet reactivity found before and after RBC transfusion in
our studies, both in vitro and in vivo, can be seen as modest
but of similar magnitude to that found in pharmacodynamic
studies between carriers and noncarriers of the loss-of-
function allele cytochrome P450 2C19*2 (24,25), an effect
well correlated with an increase in ischemic events (26,27).
We acknowledge that the increase in platelet reactivity
observed in our study is of moderate magnitude, but we
believe that it may be a plausible explanation for the detri-
mental effect of RBC transfusion found in clinical studies
(4,6,10,12). In patients with ACS, an increase in platelet
reactivity due to the transfusion itself, or potentialized by the
cessation of antiplatelet agents, seem to lead to a clinical
situation of high risk for ischemic events, especially when
added to the detrimental physiological impact of blood loss
itself. A recent meta-analysis supports the detrimental effect
of blood transfusion in high-risk situations such as
myocardial infarction, but there is a lack of analysis of po-
tential confounders such as treatment cessation (13,28). The
potential role of the P2Y12 pathway highlighted in our study
suggests that interruption of clopidogrel, prasugrel, or
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of transfusion, while aspirin interruption may be less of a
concern considering the data from our study on the AA
pathway.
Conclusions
RBC transfusion exposes patients to an increase in platelet
reactivity, an effect that is predominantly observed in the
ADP-P2Y12 receptor pathway. The link with an increase in
ischemic events in transfused patients due to an increase in
platelet reactivity remains to be demonstrated, but we sug-
gest that the risks and beneﬁts of transfusion should be
weighed on an individual basis in patients with ACS until a
randomized controlled trial of conservative versus liberal
treatment of anemic patients with ACS clariﬁes this issue.
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